ARISTOCORT A Drug Patent Profile

When do Aristocort A patents expire, and what generic alternatives are available?

Aristocort A is a drug marketed by Astellas and is included in ten NDAs.

The generic ingredient in ARISTOCORT A is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aristocort A

A generic version of ARISTOCORT A was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for ARISTOCORT A

US Patents:	0
Applicants:	1
NDAs:	10
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	4,513
DailyMed Link:	ARISTOCORT A at DailyMed

Recent Clinical Trials for ARISTOCORT A

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Innovaderm Research Inc.	Phase 4
National Center for Research Resources (NCRR)	N/A
Mayo Clinic	N/A

See all ARISTOCORT A clinical trials

US Patents and Regulatory Information for ARISTOCORT A

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	083017-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	OINTMENT;TOPICAL	080750-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	088819-001	Oct 16, 1984		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	OINTMENT;TOPICAL	088780-001	Oct 1, 1984		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	088818-001	Oct 16, 1984		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	083016-005	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for ARISTOCORT A

Last updated: February 12, 2026

Overview

ARISTOCORT A (triamcinolone acetonide) is a corticosteroid used primarily for anti-inflammatory and immunosuppressive applications. It is available in various formulations, including topical, injectable, and intra-articular. Its market is driven primarily by inflammatory, allergic, and autoimmune conditions.

Market Size and Growth

The global corticosteroid market, which includes ARISTOCORT A, was valued at approximately USD 2.8 billion in 2021 and is projected to reach USD 4.1 billion by 2026, registering a compound annual growth rate (CAGR) of around 8%. This growth rate reflects increased prevalence of autoimmune and allergic diseases, expanding indications, and the ongoing development of novel formulations.

Key Factors

• Prevalence of Target Diseases: Autoimmune disorders like rheumatoid arthritis, asthma, and allergic dermatitis drive steady demand.
• Regulatory Approvals and Guidelines: Regulatory acceptance influences market expansion. ARISTOCORT A's approval status varies across markets but remains a standard corticosteroid choice.
• Pricing and Reimbursement: Variations across regions impact revenues. Developed markets such as the US and Europe typically have higher reimbursement rates.
• Competitive Landscape: The corticosteroid segment contains several generic equivalents, pressuring pricing but maintaining stable demand.

Market Segments

1. Topical formulations: The largest revenue share, applied in dermatological conditions.
2. Injectables: Used for intra-articular injections, with demand driven by arthritis treatment.
3. Inhalation forms: Applied for asthma and COPD, though ARISTOCORT A's specific inhalation formulations are limited compared to other corticosteroids.

Pricing Trends

• Average retail prices in the US for ARISTOCORT A injections range from USD 50 to USD 150 per vial, depending on dosage and formulation.
• Market competition from generics has suppressed prices, with biosimilars and alternative corticosteroids contending for market share.

Financial Outlook

• Revenue Projections: Based on current market penetration and growth assumptions, ARISTOCORT A's sales are expected to grow at a CAGR of approximately 4%-6% over the next five years.
• Patent Status: The drug faces patent expiry risks, increasing generic competition. No recent patents are reported, which has contributed to price erosion.
• R&D Investment: Companies are exploring novel delivery systems and combination therapies to extend lifecycle and expand indications, influencing future revenue streams.

Regulatory and Market Entry Considerations

• Entry into emerging markets faces regulatory hurdles but promises growth due to increasing healthcare expenditure.
• Reimbursement policies favor established corticosteroids like ARISTOCORT A, but new competitors could influence market share.

Conclusion

ARISTOCORT A remains a core corticosteroid medication with stable demand driven by its efficacy and safety profile. The market is experiencing moderate growth, hindered by generic competition and patent expirations. Financial performance hinges on pricing strategies, adoption rates, and regulatory landscape dynamics.

---

Key Takeaways

• The global corticosteroid market is projected to grow at an 8% CAGR, driven by increased disease prevalence and expanding indications.
• ARISTOCORT A's revenues are stable but face pressure from generics and patent expiration.
• Future growth depends on new formulation development, expansion into emerging markets, and navigating regulatory environments.

---

FAQs

1. How does ARISTOCORT A compare to other corticosteroids in the market?
ARISTOCORT A is comparable to other corticosteroids in efficacy but competes primarily on brand reputation, formulation availability, and regional regulatory approval.

2. What are the main risks facing ARISTOCORT A's market position?
Patent expiration, generic competition, and potential regulatory restrictions on corticosteroid use pose risks to market share.

3. Are there new formulations or delivery methods in development?
Research focuses on sustained-release injections, topical gels, and combination therapies to enhance patient compliance and extend patent exclusivity.

4. What markets offer the most growth potential?
Emerging markets in Asia and Latin America present potential for expanded sales due to rising healthcare infrastructure and disease burden.

5. How are reimbursement policies affecting ARISTOCORT A?
Generally favorable in developed countries, but policies are evolving, and competition from generics can pressure pricing and reimbursement levels.

---

Sources

[1] MarketWatch, "Corticosteroids Market Size, Share & Trends Analysis," 2022.
[2] Documents from the FDA and EMA regarding ARISTOCORT A approval status.
[3] IQVIA data on corticosteroid prescription trends, 2022.